Shanghai Fosun Pharmaceutical : INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021（H SHARES）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

INTERIM RESULTS ANNOUNCEMENT

FOR THE SIX MONTHS ENDED 30 JUNE 2021

The board (the ''Board'') of directors (the ''Directors'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') is pleased to announce the unaudited interim results of the Company and its subsidiaries (collectively, the ''Group'') for the six months ended 30 June 2021 (the ''Reporting Period'').

- 1 -

FINANCIAL HIGHLIGHTS

Interim Condensed Consolidated Statement of Profit or Loss

For the six months ended 30 June 2021

		For the six months ended 30 June
		2021		2020
	Notes	RMB'000	RMB'000
		(Unaudited)	(Unaudited)
REVENUE	4	16,877,537		13,965,179
Cost of sales		(8,110,878)	(6,215,872)
Gross profit		8,766,659		7,749,307
Other income	5	141,714		180,429
Selling and distribution expenses		(4,356,975)	(3,931,067)
Administrative expenses		(1,505,057)	(1,322,239)
Research and development expenses		(1,561,885)	(1,204,425)
Impairment losses on financial assets		(14,804)	(42,765)
Other gains	6	1,645,255		603,622
Other expenses		(338,367)	(52,138)
Interest income		116,605		96,436
Finance costs	7	(420,725)	(427,878)
Share of profits and losses of:
Joint ventures		(93,817)	(46,558)
Associates		925,626		698,964
PROFIT BEFORE TAX	8	3,304,229		2,301,688
Income tax expense	9	(550,647)	(392,081)
PROFIT FOR THE PERIOD		2,753,582		1,909,607
Attributable to:
Owners of the parent		2,482,373		1,714,710
Non-controlling interests		271,209		194,897
		2,753,582		1,909,607
EARNINGS PER SHARE ATTRIBUTABLE TO
ORDINARY EQUITY HOLDERS OF THE PARENT	11
Basic
- For profit for the period		RMB0.97 Yuan	RMB0.67 Yuan
Diluted
- For profit for the period		RMB0.97 Yuan	RMB0.67 Yuan

- 2 -

Interim Condensed Consolidated Statement of Comprehensive Income

For the six months ended 30 June 2021

	For the six months ended 30 June
	2021		2020
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
PROFIT FOR THE PERIOD	2,753,582	1,909,607
OTHER COMPREHENSIVE INCOME
Other comprehensive loss that may be reclassified to profit or
loss in subsequent periods:
Exchange differences on translation of foreign operations	(201,712)	(255,609)
Share of other comprehensive loss of joint ventures	(804)	(1,115)
Share of other comprehensive income of associates	54,912		29,073
Net other comprehensive loss that may be reclassified to
(147,604)
profit or loss in subsequent periods	(227,651)
Other comprehensive income that will not be reclassified to
profit or loss in subsequent periods:
Equity investments designated at fair value through
other comprehensive income	5,200
Changes in fair value		3,727
Income tax effect	(780)	24
	4,420		3,751
Share of other comprehensive income of associates	10,725		68,933
Net other comprehensive income that will not be reclassified to	15,145
profit or loss in subsequent periods		72,684
OTHER COMPREHENSIVE LOSS FOR THE PERIOD,
(132,459)
NET OF TAX	(154,967)
TOTAL COMPREHENSIVE INCOME
FOR THE PERIOD	2,621,123		1,754,640
Attributable to:	2,385,072
Owners of the parent		1,660,547
Non-controlling interests	236,051		94,093
	2,621,123		1,754,640

- 3 -

Interim Condensed Consolidated Statement of Financial Position

30 June 2021

		30 June		31 December
		2021	2020
	Notes	RMB'000		RMB'000
		(Unaudited)		(Audited)
NON-CURRENT ASSETS
Property, plant and equipment		11,986,909	12,579,873
Right-of-use assets		2,574,667	2,666,402
Goodwill		8,622,217	8,677,249
Other intangible assets		9,730,364	9,577,741
Investments in joint ventures		349,077	381,616
Investments in associates		22,447,860	21,870,966
Equity investments designated at fair value
through other comprehensive income		6,243	1,043
Financial assets at fair value through profit or loss		1,459,128	1,460,769
Deferred tax assets		232,984	244,937
Other non-current assets		1,807,055		1,083,724
Total non-current assets		59,216,504	58,544,320
CURRENT ASSETS
Inventories		5,485,618	5,162,800
Trade and bills receivables	12	6,028,237	4,807,059
Prepayments, other receivables and other assets		3,462,140	2,554,165
Financial assets at fair value through profit or loss		3,267,854	1,970,096
Debt investments at fair value through
other comprehensive income		472,998	628,881
Cash and bank balances		10,489,133		9,961,802
Total current assets		29,205,980		25,084,803

- 4 -

		30 June	31 December
		2021		2020
	Notes	RMB'000	RMB'000
		(Unaudited)	(Audited)
CURRENT LIABILITIES
Trade and bills payables	13	3,745,584		3,289,021
Other payables and accruals		6,582,248		5,597,564
Interest-bearing bank and other borrowings		15,852,411		14,488,946
Lease liabilities		140,052		151,084
Contract liabilities		1,447,288		1,020,309
Tax payable		389,670		325,429
Total current liabilities		28,157,253		24,872,353
NET CURRENT ASSETS		1,048,727		212,450
TOTAL ASSETS LESS CURRENT LIABILITIES		60,265,231		58,756,770
NON-CURRENT LIABILITIES
Interest-bearing bank and other borrowings		8,513,509		8,475,685
Lease liabilities		706,945		627,291
Deferred tax liabilities		2,935,378		2,852,997
Deferred income		506,250		482,201
Other long term liabilities		277,854		269,488
Contract liabilities		285,708		121,712
Total non-current liabilities		13,225,644		12,829,374
Net assets		47,039,587		45,927,396
EQUITY
Equity attributable to owners of the parent
Issued share capital		2,562,899		2,562,899
Reserves		35,241,150		34,375,748
		37,804,049		36,938,647
Non-controlling interests		9,235,538	8,988,749
Total equity		47,039,587		45,927,396

- 5 -